Cathie Wood’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,066,665
Closed -$3.93M 196
2025
Q4
$3.93M Buy
3,066,665
+44,937
+1% +$60.4K 0.03% 121
2025
Q3
$3.93M Sell
3,021,728
-133,327
-4% -$175K 0.02% 127
2025
Q2
$3.79M Sell
3,155,055
-297,835
-9% -$330K 0.03% 112
2025
Q1
$3.73M Buy
3,452,890
+129,201
+4% +$181K 0.04% 113
2024
Q4
$5.82M Sell
3,323,689
-5,626,076
-63% -$10.5M 0.05% 105
2024
Q3
$17.3M Sell
8,949,765
-3,729,626
-29% -$7.3M 0.16% 69
2024
Q2
$22.4M Sell
12,679,391
-363,049
-3% -$887K 0.2% 64
2024
Q1
$35.3M Buy
+13,042,440
New +$31.5M 0.24% 60

Other funds holding LAB

Cathie Wood's LAB Position: Q1 2026 in Review

Cathie Wood sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 3,066,665 shares — an estimated $3.93M sold.

Cathie Wood first reported a position in LAB in Q1 2024 and held it in 8 quarters. The position peaked at $35.3M in Q1 2024. 156 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Cathie Wood reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
  • Cathie Wood sold 3,066,665 Standard BioTools shares in Q1 2026, an estimated $3.93M.
  • Cathie Wood first reported a position in Standard BioTools in Q1 2024 and held it in 8 quarters.
  • Cathie Wood's Standard BioTools position peaked at $35.3M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on ARK Investment Management's 13F filing for Q1 2026, filed 12 May 2026.